Silke Appel-Dingemanse
Clinical Pharmacology Department
Novartis Pharma AG
CH-4002 Basel
Switzerland
Name/email consistency: high
- Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Appel-Dingemanse, S. Clin. Pharmacokinet (2002)
- Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Appel-Dingemanse, S., Hirschberg, Y., Osborne, S., Pommier, F., McLeod, J. Eur. J. Clin. Pharmacol. (2001)
- The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Appel-Dingemanse, S., Horowitz, A., Campestrini, J., Osborne, S., McLeod, J. Aliment. Pharmacol. Ther. (2001)